|
Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therape... Oct. 17, 2019 /PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of Pre-Clinical Development, provided a presentation on Palatin's oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Symposium on Peptide Therapeutics in Hangzhou, China. https://de.advfn.com/p.php?pid=nmona&article=80940170 |
|
| aus der Diskussion: | Palatin Technology / voraussichtliches Marktpotential von 1,3 Mrd $ bis 2020 allein in USA |
| Autor (Datum des Eintrages): | bonDiacomova (17.10.19 19:35:55) |
| Beitrag: | 4,809 von 5,764 (ID:61713054) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |